Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridayNov 11, 2016 1:11 pm

Towerstream Corp. (TWER) Increases Q3 Adjusted EBITDA; Shares Higher

Shares of Towerstream (NASDAQ: TWER) are higher in late-morning trade, driven by third-quarter guidance for Adjusted EBITDA from Continuing Operations of $525,000 excluding non-recurring expenses. Among other notes, the company reported a reduction in long-term debt to $32 million from $37 million. A conference call to discuss results for the third quarter 2016 will be held November 16, 2016 at 5 p.m. ET. To view the full press release, visit: http://nnw.fm/vKlW9 About Towerstream Corporation Towerstream Corporation (TWER) is a leading Fixed-Wireless Fiber Alternative company delivering high-speed Internet access to businesses. The Company offers broadband services in 12 urban markets including New York City, Boston,…

Continue Reading

FridayNov 11, 2016 1:10 pm

GainClients, Inc. (GCLT) Targets Emerging Digital Trends in Real Estate Industry

GainClients’ (OTC: GCLT) progressive GCard networking system enables agents and brokers the ability to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions. As the company pursues avenues to expand the reach of its GCard network, it employs a growth strategy supported by key industry partnerships and licensing arrangements. “Strategic partnerships are an important component of GainClients’ growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies’ proprietary technologies to the real…

Continue Reading

FridayNov 11, 2016 1:08 pm

Medical Transcription Billing, Corp. (MTBC) Provides Essential Element of Broader Health Care Initiatives

Considered by some to be the most important piece of health care reform in three decades, The Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, among other things, encouraged the use of electronic health records (EHR) to significantly improve medical services. Integrated charting services are a core part of Medical Transcription Billing, Corp.’s (NASDAQ: MTBC) (NASDAQ: MTBCP) proprietary HER technology, ChartsPro, which makes the delivery of service more efficient and enables practitioners to reach ‘Meaningful Use’ standards set forth by HITECH. “MTBC’s charting services are designed to help physicians generate accurate, timely patient charts and better…

Continue Reading

ThursdayNov 10, 2016 2:40 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 10, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GALT 35.08% – News: Announces positive interim clinical data for GR-MD-02 for the treatment of skin disease ETRM 33.20% – News: Posts Q3; net loss of $6.5 million, $0.17 per share, on sales of $296,760 MVIS 22.60% – News: Partners with STMicroelectronics (NYSE: STM) to market Laser Beam Scanning technology RXII 14.72% – News: Trims Q3 net loss to $2.2 million from $2.5 million last year FCSC 16.38% – News: Names board-certified dermatologist and…

Continue Reading

ThursdayNov 10, 2016 2:04 pm

Imprimis Pharmaceuticals, Inc. (IMMY) Inks New Supply Agreement; Shares Climb

Imprimis Pharmaceuticals (NASDAQ: IMMY) is trading 11% higher mid-morning, driven by the company’s product purchase and supply agreement with the specialty pharmacy division of one of the nation's largest pharmacy benefit managers (PBMs) to supply Imprimis' complete formulary of low-cost compounded medications through the PBM's national network of specialty pharmacies. To view the full press release, visit: http://nnw.fm/Y7hHj About Imprimis Pharmaceuticals Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states.  The company's unique business model drives patient access and affordability to many critical medicines.  Headquartered in…

Continue Reading

ThursdayNov 10, 2016 10:58 am

Galectin Therapeutics, Inc. (GALT) Shares Surge on Positive Interim Data for Lead Candidate GR-MD-02

Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 30% this morning after delivering positive interim clinical data for its lead candidate GR-MD-02 to treat psoriasis and atopic dermatitis. The company also announced its plans to identify a strategic partnership to further develop the drug candidate for the treatment of serious skin diseases. To view the full press release, visit: http://nnw.fm/d95Ap About Galectin Therapeutics Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to…

Continue Reading

ThursdayNov 10, 2016 10:55 am

Moxian, Inc. (MOXC) Solutions Help Merchants Build Strong Customer Relationships to Keep Competitive Edge

Customer satisfaction is a bedrock for any organization, and the most successful businesses are the ones who dedicate time to cultivate customer-merchant relationships. By listening to consumers, engaging in ongoing communication, rewarding loyalty, and efficiently training employees, businesses are privy to repeat business and word of mouth marketing. While social media creates a wealth of opportunity to build customer relationships, it takes considerable time, knowledge and dedication to pull-off a successful campaign. “Businesses, especially small businesses, are looking to creative outside marketing services to better interact with their consumers. Moxian, Inc. (OTCQB: MOXC) offers exactly such services and more. MOXC…

Continue Reading

WednesdayNov 09, 2016 3:39 pm

America Votes Trump; Investors Pounce on Healthcare Stocks

President-elect Donald Trump has long voiced his opposition of ObamaCare and the broader healthcare system, and though his stance on regulating drug prices remains uncertain, drug companies are likely to enjoy lesser scrutiny than they would from a Clinton Administration. In today’s market, here are several healthcare stocks trading higher near market close: Cigna Corp. (NYSE: C) Humana, Inc. (NYSE: HUM) Aetna, Inc. (NYSE: AET) UnitedHealth Group, Inc. (NYSE: UNH) Actinium Pharmaceuticals, Inc. (NYSE: NTM) AmerisourceBergen Corp. (NYSE: ABC) Biogen, Inc. (NASDAQ: BIIB) About NetworkNewsBreaks NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW).…

Continue Reading

WednesdayNov 09, 2016 12:19 pm

Will the Trump Train Boost the Construction Industry?

Defying the drop in global markets and futures following Donald Trump’s presidential win, U.S. markets are higher in morning trade. If Trump achieves his vision to bring jobs back to American soil, it could mean big business for companies operating in various aspects of the building and construction trades. In today’s market, here are several construction stocks trading higher: Argan, Inc. (NYSE: AGX) Dycom Industries, Inc. (NYSE: DY) Emcor Group, Inc. (NYSE: EME) Comfort Systems USA, Inc. (NYSE: FIX) Granite Construction, Inc. (NYSE: GVA) Myr Group, Inc. (NYSE: MYRG) NV5 Group, Inc. (NYSE: NVEE) About NetworkNewsBreaks NetworkNewsBreaks (NNB) provide a…

Continue Reading

WednesdayNov 09, 2016 10:17 am

Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up to Evaluate Combination in Solid Tumors Study; Shares Jump

Shares of Bristol-Myers Squibb (NYSE: BMY) and Infinity Pharmaceuticals (NASDAQ: INFI) are higher after the companies announced their clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors. The dose-escalation portion exploring IPI-549 as a monotherapy in Infinity’s phase 1 study is continuing, and the first dose-escalation cohort studying IPI-549 in combination with Opdivo, a PD-1 immune checkpoint inhibitor, is scheduled to begin this fall. To view the full press release, visit: http://nnw.fm/V4tfN About Infinity Pharmaceuticals, Inc. Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217